Salmonella: A Promising Tool in Vaccine Development and Cancer Therapy

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Targeting and Design".

Deadline for manuscript submissions: closed (10 April 2024) | Viewed by 1746

Special Issue Editor


E-Mail Website
Guest Editor
College of Veterinary Medicine, Jeonbuk National University, Iksan 54596, Republic of Korea
Interests: veterinary vaccines; delivery systems; Salmonella vectored vaccines; Salmonella in cancer therapy; oral mRNA vaccine; Salmonella pathophysiology
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The ability of live attenuated Salmonella to encode and deliver several classes of recombinant antigens to its host is being leveraged in the repurposing of bacteria as a vaccine vector against numerous infectious diseases and cancer. Heterologous antigens expressed by Salmonella can be delivered to specific subcellular locations in host cells via the manipulation of T3SS effector proteins. Furthermore, the ability to directly deliver antigens to professional APCs results in the elicitation of potent cellular immune responses through prominent CD8+ T cell priming.

Bacteria-based cancer therapy is a versatile platform that can be engineered as a standalone or combined with other therapies to improve prognosis in cancer. With its immunostimulatory property and ability to grow in hypoxic and immunosuppressive tumor microenvironments, Salmonella can direct immune responses toward tumors. When administered as a standalone, it either upregulates inflammasome pathways or promotes TNF-α mediated hemorrhage, which results in tumor necrosis. Salmonella can be genetically modified to encode and deliver an array of molecules that might be otherwise toxic if administered systemically, including pro-drugs, small interfering RNAs, nanobodies, toxins, and immunomodulators.

Therefore, through the use of Salmonella-mediated vaccine delivery in treating infectious diseases and cancer, it is expected that the limitations of conventional therapies, such as off-target toxicities and poor bioavailability, can be overcome.

For this Special Issue, we invite the submission of original research articles, communications, and reviews that describe the potential use of Salmonella as a biological delivery vehicle for the therapy of cancer and infectious diseases.

We look forward to receiving your contributions.

Prof. Dr. John Hwa Lee
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Salmonella
  • Salmonella-vectored vaccines
  • recombinant vaccine
  • Salmonella-mediated cancer therapy
  • novel delivery systems
  • mucosal delivery
  • Immune response
  • delivery of DNA
  • controlled release systems

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

18 pages, 7084 KiB  
Article
Inflammation-Related Immune-Modulatory SLURP1 Prevents the Proliferation of Human Colon Cancer Cells, and Its Delivery by Salmonella Demonstrates Cross-Species Efficacy against Murine Colon Cancer
by Amal Senevirathne, Ram Prasad Aganja, Chamith Hewawaduge and John Hwa Lee
Pharmaceutics 2023, 15(10), 2462; https://doi.org/10.3390/pharmaceutics15102462 - 13 Oct 2023
Cited by 2 | Viewed by 1369
Abstract
This study investigates the anticancer properties of the α7-nAChR antagonist SLURP1 with a specific focus on its effect as an inflammation modulator on human colorectal cancer cell lines Caco2, Colo320DM, and H508 cells. The investigation includes the evaluation of cell cycle arrest, cell [...] Read more.
This study investigates the anticancer properties of the α7-nAChR antagonist SLURP1 with a specific focus on its effect as an inflammation modulator on human colorectal cancer cell lines Caco2, Colo320DM, and H508 cells. The investigation includes the evaluation of cell cycle arrest, cell migration arrest, endogenous expression of SLURP1 and related proteins, calcium influx, and inflammatory responses. The results demonstrate that SLURP1 not only inhibits cell proliferation but also has the potential to arrest the cell cycle at the G1/S interface. The impact of SLURP1 on cell cycle regulation varied among cell lines, with H508 cells displaying the strongest response to exogenous SLURP1. Additionally, SLURP1 affects the nuclear factor kappa B expression and effectively reverses inflammatory responses elicited by purified lipopolysaccharides in H508 and Caco2 cells. This study further confirmed the expression of human SLURP1 by Salmonella, under Ptrc promoter, through Western blot analysis. Moreover, Salmonella secreting SLURP1 revealed a significant tumor regression in a mouse CT26 tumor model, suggesting the cross-species anticancer potential of human SLURP1. However, further investigations are required to fully understand the mechanisms underlying SLURP1’s ability to prevent cancer proliferation and its protective function in humans. Full article
Show Figures

Figure 1

Back to TopTop